Project Grant R01CA311063
Award Date 8/5/26
Completion Date 7/31/31
Dollars Obligated $578K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
- The National Cancer Institute awarded Carnegie Mellon University $521,523 on July 6, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate multi-faceted regulation of dynamic sumoylation at alternative lengthening of telomeres (ALT) cancer telomeres. The project, R01CA308360, addresses the lack of therapeutic targets for ALT cancers, which represent a subset of malignancies that extend telomeres through homology-directed repair pathways occurring in...
- The National Cancer Institute awarded Sloan-Kettering Institute For Cancer Research $263,073 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research identifying genetic factors mediating alternative lengthening of telomeres (ALT) in cancer. The research targets ALT, a recombination-based telomere maintenance mechanism present in 10–15 percent of cancers, particularly sarcomas and gliomas. The investigator will conduct three aims: examining how chromatin...
- The National Cancer Institute awarded the University of Pittsburgh $649,620 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to examine Medicare Advantage plan impacts on cancer care access, quality, and outcomes for older adults. The project investigates whether Medicare Advantage's limited provider networks create barriers to timely specialty care for patients with the four most prevalent cancers—breast, colorectal, lung, and prostate. The research employs...
- The National Cancer Institute awarded the University of Pittsburgh $673,522 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to support comprehensive biochemical and structural analysis of nucleotide excision repair (NER), the primary human pathway for removing DNA lesions caused by solar UV irradiation and environmental toxins. The recipient will characterize the dynamic progression of NER from damage recognition and verification through dual incision, using...
- The National Cancer Institute awarded the University of Pittsburgh $261,662 on December 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to conduct an integrated in silico and in vivo genetic screening study identifying subtype-specific hepatocellular carcinoma genetic dependencies. The research combines computational deep-learning prediction of genetic dependencies with in vivo loss-of-function screening in murine hepatocellular carcinoma models representing the Hoshida...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded New York University $701,574 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate APOBEC3-induced mutagenesis in cancer development and therapy resistance. The funded research develops experimental and bioinformatics methods to track de novo generation of specific mutational signatures (SBS2 and SBS13) induced by individual...
- The National Cancer Institute awarded the University of North Carolina at Chapel Hill $388,439 on July 8, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop genetically encoded fluorescent reporter systems that detect pediatric cancer biomarkers in living cells. The funded work engineers two cell reporter platforms to advance understanding of alternative lengthening of telomeres (ALT), a telomere maintenance mechanism prevalent in aggressive pediatric tumors...
- The National Cancer Institute awarded the University of Pittsburgh $164,190 on January 21, 2026, under the Cancer Research Manpower program (CFDA 93.398) to conduct computational and wet lab research on metastatic breast cancer genomics and tumor evolution tracking. The project applies machine learning and phylogeny analysis tools—including transformer models—to identify recurrent patterns of gene deletions in metastatic breast cancer samples. The work integrates genomic data from the AURORA...
- The National Cancer Institute awarded the University of Pittsburgh $408,829 on June 12, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and refine a high-throughput single-cell morphological analysis pipeline for identifying and targeting polyploid giant cancer cells (PGCCs) in breast cancer treatment resistance. The recipient will improve the robustness and accuracy of its preliminary single-cell analysis pipeline across diverse staining and imaging...
- The National Cancer Institute, part of the National Institutes of Health under the Department of Health and Human Services, awarded Duke University $302,524 on September 10, 2025, under the Cancer Research Manpower program (CFDA 93.398). The award funds a postdoctoral research fellowship (F32) to investigate the role of SMARCAL1, an annealing helicase, in promoting glioma cell proliferation and suppressing tumor-intrinsic inflammation in alternative lengthening of telomeres (ALT)–positive...